Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients

ISSN
1756-9966
Date Issued
2015-05-19
Author(s)
Heublein, Sabine
Mayr, Doris
Egger, Markus
Karsten, Uwe
Goletz, Steffen
Angele, Martin
Jeschke, Udo
Ditsch, Nina
DOI
10.1186/s13046-015-0152-7
Abstract
Mucin-1 (MUC1, CD227), more widely known as CA15-3, is an abundantly expressed epithelial cell surface antigen and has evolved to be the most predictive serum tumour marker in breast cancer. PankoMab-GEX™, which is currently being evaluated for its therapeutic efficacy in a phase IIb clinical trial, is a glyco-optimized anti-MUC1 antibody specifically recognizing a tumour-associated MUC1 epitope (TA-MUC1). The current study aimed to analyse the immunoreactivity of PankoMabGEX™ and its correlation with established clinico-pathological variables including 10-year and overall survival in a large cohort of breast cancer patients.